Is Hepion Pharmaceuticals Stock a Good Investment?
Hepion Pharmaceuticals Investment Advice | HEPA |
- Examine Hepion Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Hepion Pharmaceuticals' leadership team and their track record. Good management can help Hepion Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Hepion Pharmaceuticals' business and its evolving consumer preferences.
- Compare Hepion Pharmaceuticals' performance and market position to its competitors. Analyze how Hepion Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Hepion Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Hepion Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Hepion Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Hepion Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Hepion Pharmaceuticals Stock
Researching Hepion Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 1.16. The company recorded a loss per share of 4.4. Hepion Pharmaceuticals last dividend was issued on the 3rd of June 2019. The entity had 1:20 split on the 11th of May 2023.
To determine if Hepion Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Hepion Pharmaceuticals' research are outlined below:
| Hepion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Hepion Pharmaceuticals has high historical volatility and very poor performance | |
| Hepion Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Hepion Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (48.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hepion Pharmaceuticals currently holds about 59.15 M in cash with (40.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hepion Pharmaceuticals has a frail financial position based on the latest SEC disclosures |
Hepion Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Hepion Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Hepion Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hepion Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Hepion Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Hepion Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-16 | 2022-03-31 | -0.13 | -0.09 | 0.04 | 30 | ||
2022-11-14 | 2022-09-30 | -0.17 | -0.11 | 0.06 | 35 | ||
2021-11-15 | 2021-09-30 | -0.19 | -0.12 | 0.07 | 36 | ||
2021-05-14 | 2021-03-31 | -0.2 | -0.12 | 0.08 | 40 | ||
2020-08-12 | 2020-06-30 | -0.5 | -0.58 | -0.08 | 16 | ||
2021-08-16 | 2021-06-30 | -0.19 | -0.1 | 0.09 | 47 | ||
2021-03-31 | 2020-12-31 | -0.2 | -0.29 | -0.09 | 45 | ||
2019-11-14 | 2019-09-30 | -0.64 | -0.53 | 0.11 | 17 |
Know Hepion Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hepion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hepion Pharmaceuticals backward and forwards among themselves. Hepion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Hepion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.7 K | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 175 | Advisor Group Holdings, Inc. | 2024-06-30 | 113 | Macquarie Group Ltd | 2024-06-30 | 88.0 | Group One Trading, Lp | 2024-06-30 | 84.0 | Ubs Group Ag | 2024-06-30 | 70.0 | Advisornet Financial, Inc | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-06-30 | 46.0 | Barclays Plc | 2024-06-30 | 16.0 | Armistice Capital, Llc | 2024-06-30 | 516 K | Vanguard Group Inc | 2024-09-30 | 90.9 K |
Hepion Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.83 M.Market Cap |
|
Hepion Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.70) | (2.84) | |
| Return On Capital Employed | (3.78) | (3.59) | |
| Return On Assets | (2.70) | (2.84) | |
| Return On Equity | (6.72) | (6.38) |
Determining Hepion Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Hepion Pharmaceuticals is a good buy. For example, gross profit margin measures Hepion Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Hepion Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Hepion Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Hepion Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Hepion Pharmaceuticals' management manipulating its earnings.
Evaluate Hepion Pharmaceuticals' management efficiency
Hepion Pharmaceuticals has return on total asset (ROA) of (0.9282) % which means that it has lost $0.9282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8952) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -2.84. The current year's Return On Capital Employed is expected to grow to -3.59. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 24 M, whereas Non Currrent Assets Other are forecasted to decline to about 228.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.83 | 1.74 | |
| Tangible Book Value Per Share | 1.83 | 1.93 | |
| Enterprise Value Over EBITDA | 0.03 | 0.04 | |
| Price Book Value Ratio | 1.77 | 1.86 | |
| Enterprise Value Multiple | 0.03 | 0.04 | |
| Price Fair Value | 1.77 | 1.86 | |
| Enterprise Value | -2 M | -2.1 M |
Effective leadership at Hepion Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 1.813 |
Basic technical analysis of Hepion Stock
As of the 21st of November, Hepion Pharmaceuticals retains the Market Risk Adjusted Performance of 0.0175, risk adjusted performance of 0.0114, and Downside Deviation of 4.97. Hepion Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Hepion Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hepion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hepion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hepion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hepion Pharmaceuticals' Outstanding Corporate Bonds
Hepion Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hepion Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hepion bonds can be classified according to their maturity, which is the date when Hepion Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Hepion Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Hepion Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0114 | |||
| Market Risk Adjusted Performance | 0.0175 | |||
| Mean Deviation | 3.9 | |||
| Semi Deviation | 4.43 | |||
| Downside Deviation | 4.97 | |||
| Coefficient Of Variation | 27650.1 | |||
| Standard Deviation | 5.56 | |||
| Variance | 30.91 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.62) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0075 | |||
| Maximum Drawdown | 33.54 | |||
| Value At Risk | (8.11) | |||
| Potential Upside | 8.06 | |||
| Downside Variance | 24.72 | |||
| Semi Variance | 19.63 | |||
| Expected Short fall | (4.97) | |||
| Skewness | 1.34 | |||
| Kurtosis | 5.36 |
| Risk Adjusted Performance | 0.0114 | |||
| Market Risk Adjusted Performance | 0.0175 | |||
| Mean Deviation | 3.9 | |||
| Semi Deviation | 4.43 | |||
| Downside Deviation | 4.97 | |||
| Coefficient Of Variation | 27650.1 | |||
| Standard Deviation | 5.56 | |||
| Variance | 30.91 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.62) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0075 | |||
| Maximum Drawdown | 33.54 | |||
| Value At Risk | (8.11) | |||
| Potential Upside | 8.06 | |||
| Downside Variance | 24.72 | |||
| Semi Variance | 19.63 | |||
| Expected Short fall | (4.97) | |||
| Skewness | 1.34 | |||
| Kurtosis | 5.36 |
Consider Hepion Pharmaceuticals' intraday indicators
Hepion Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Hepion Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Hepion Pharmaceuticals time-series forecasting models is one of many Hepion Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hepion Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Hepion Stock media impact
Far too much social signal, news, headlines, and media speculation about Hepion Pharmaceuticals that are available to investors today. That information is available publicly through Hepion media outlets and privately through word of mouth or via Hepion internal channels. However, regardless of the origin, that massive amount of Hepion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Hepion Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Hepion Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Hepion Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Hepion Pharmaceuticals alpha.
Hepion Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Hepion Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Hepion Pharmaceuticals Corporate Management
| BSc BSc | CEO Pres | Profile | |
| Patrick Mayo | Senior Pharmacology | Profile | |
| John Cavan | Chief Officer | Profile | |
| Sharen Pyatetskaya | Director Relations | Profile | |
| Todd MD | Chief Officer | Profile | |
| Daniel Trepanier | Senior Development | Profile | |
| Daren Ure | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.40) | Return On Assets (0.93) | Return On Equity (1.90) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Hepion Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.